Pepti Review: $99 Semaglutide, and the Ladder That Contradicts It

Pepti (hellopepti.com) advertises the lowest semaglutide rung we have filed this year — $99 a month, flat, at every titration dose, cancel any time. Tirzepatide is $199 on the same terms. Multiply those out and a year of semaglutide is $1,188 and a year of tirzepatide is $2,388, with no step-up at month two and no surcharge when your dose goes up.¹

That is a genuinely good number, and it comes with a problem we could not resolve. Both halves belong in the same review.

The rung we filed

Pepti's catalogue is a 68-SKU price list, and the structure is unusually simple: every product has one monthly subscription price, and an optional one-time purchase at exactly 1.25 times that price. Semaglutide is $99 a month or $124 once; tirzepatide is $199 or $249; the multiplier holds across the catalogue. There is no prepay tier, so there is no prepay rung to mistake for a monthly one — which is the trap that puts most cheap figures on a board wrongly, and the reason we hold every filed price to the month-to-month rung.

The subscription terms say cancellation takes effect at the end of the current cycle, with no minimum term and an option to pause for up to 90 days. Against a $1,188 year for semaglutide, that flexibility is the second-best thing on offer here.

The contradiction, reported as it stands

Pepti's cost page states, in its own words, that all doses carry one flat monthly price and that the price is the same at every titration step. Sitting in the production data behind its semaglutide and tirzepatide pages is a per-dose ladder that says otherwise: $299 at 0.25 mg rising to $449 at 2.4 mg for semaglutide, and $349 rising to $549 at 15 mg for tirzepatide.

Nothing on the site renders that ladder. It is not on any page, not in the purchase flow, and no code we could find reads it. The checkout endpoint accepts only POST requests, so we could not walk a real transaction to the price and settle it.

We are not going to pretend that resolves cleanly. A dose-tiered ladder averaging roughly three times the headline, sitting in live production data, is a material open question — if it were ever switched on, a reader at a 2.4 mg maintenance dose would be paying $5,388 a year rather than $1,188. Our position is that $99 and $199 are what Pepti currently shows, sells and repeats across five separate surfaces, so those are the figures we file; and that the ladder is unresolved rather than disproved. If you sign up, screenshot the price you are quoted at your maintenance dose. Dose-tiered pricing is trap two in the true monthly cost of a GLP-1, and the labeled titration schedule tells you which dose you are actually budgeting for.

Two more places the site disagrees with itself

Pepti publishes a 36-state list on four separate surfaces — its shipping page, its state-availability page, its provider page and its own homepage title — and its terms of service say the service is available in all 50. Four corroborating surfaces beat one outlier, so treat 36 as the operative number and check your own state against the published list before you get attached to the price. At-home blood panels ship to all 50 regardless.

The site also tells you twice, in two different documents, when your card is charged. The how-it-works page says you pay nothing until a physician approves treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake. The refund policy is the operative document, so assume you are charged first and refunded if you are declined — the policy does promise a full refund on provider denial, in five to ten business days.

What is on the shelf, and what should not be

Pepti's catalogue runs far past GLP-1s: nasal sprays, recovery peptides, anti-aging injectables, a nootropic line, and a DSIP sleep product at $189 a month. It also stocks retatrutide at $399 a month, melanotan II and IGF-1 LR3.

Retatrutide is not approved anywhere, by any regulator, for any indication — it is a molecule still in trials, and we cover why that matters in retatrutide vs tirzepatide. We do not treat any of those three as a recommendable purchase, and a catalogue that lists them next to an approved-molecule compound is a catalogue that requires you to know the difference yourself.

Who is behind the prescription

Two prescribers are named with full bios, education and board certifications: Dr. Gene Lee, MD, in family medicine, and Dr. Laeeq Butt, MD, MBA, in internal medicine. Neither NPI is published, so neither can be checked against the national registry — a bio is a claim, an NPI is a record. The dispensing pharmacy is described only as an FDA-registered 503A or 503B compounder and is never named.

The regulatory screen was clean. The trading name and the legal entity returned zero company-column matches in the FDA's live warning-letter index in August 2026, in a pass whose positive control correctly returned a known 2026 letter for an unrelated seller.² Worth noting, because the neighbourhood is not: a search for the stem "pepti" surfaces a long list of peptide sellers that do carry letters. Pepti is not among them.

Where it lands on value

On sticker price nothing else we tested this month is close — $99 against The Edit's $209 and Trellis Vitality's $150. On verifiability it sits mid-pack: no NPI, no named pharmacy, a state count that its own terms contradict, and a dead price ladder we could not rule out.

If you want the cheapest verified semaglutide rung we currently track, this is it, and the cheapest semaglutide board puts it against the field. Just go in knowing which of these numbers is confirmed and which is still open, and price your own twelve months with the cost calculator. The rest of what we publish on compounded GLP-1 pricing is in our research library.